1,416 press releases in English indexed under automotive.
"Electric Vehicle Battery Housing Market: Focus on Application, Product, and Country Analysis - Analysis and Forecast, 2026-2035" has been added to ResearchAndMarkets.com's offering.
Infrastructure renewal, EV production, AI-enabled mills and low-carbon steel drive demand, while versatile carbon steel rods lead key applications Infrastructure renewal, EV production, AI-enabled mills and low-carbon steel drive demand, while versatile carbon steel rods lead key applications
140-Page Report Tracks IP Activity in the US, Europe and Asia, Plus Collaborations and Licensing Among Top Players, as Stricter Safety Regulations Push Blind Spot Systems Beyond Premium Vehicles 140-Page Report Tracks IP Activity in the US, Europe and Asia, Plus Collaborations and Licensing Among Top Players, as Stricter Safety Regulations Push Blind Spot Systems Beyond Premium Vehicles
Prioritize Asia-Pacific, power units and high-pressure components; construction machinery and automotive demand offer strong ROI opportunities. Prioritize Asia-Pacific, power units and high-pressure components; construction machinery and automotive demand offer strong ROI opportunities.
Hong Kong, Oct 9, 2026 - Cheche Group Inc. (NASDAQ: CCG) is pursuing an expansion into residential battery storage and home energy management under its “Green Mobility + Green Energy” two-pillar strategy. The planned expansion would complement its established NEV insurance technology business and support its broader “Car + Home” vision. Cheche’s existing platform connects automakers and insurance carriers to support digital insurance transactions and services. In the first half of 2026, its NEV partnerships generated approximately 1.0 million insurance policies, up 29.5% from a year earlier. Corresponding written premiums rose 23.7% to RMB3.2 billion. The company had partnerships with 18 NEV manufacturers as of June 30, 2026. This business has given Cheche experience in integrating insurance services into automakers’ customer channels. Its technology supports insurance transactions, pricing and claims processes through data integration and risk modeling. For the proposed home energy expansion, Cheche is targeting Long Way Fortune, a residential energy technology provider operating under its brand EnergyLIB. Long Way Fortune brings hardware engineering, modular battery products, and local service capabilities. Its portfolio includes modular batteries and hybrid inverters designed for both retrofit solar-plus-storage and new installations. The business operates in Australia and Singapore, with a model that includes local distribution, installation support and after-sales service. EnergyLIB is also developing home energy management functions that use electricity consumption, solar generation, weather, tariffs and battery operating data. These functions are intended to help households manage electricity costs while accounting for backup power needs and battery usage. Cheche sees a potential role for its insurance technology and business relationships in services around these energy assets, and will explore potential insurance and financing solutions that could help spread customers' upfront payments over time. These offerings remain in the planning stage and would require product development and partner arrangements. The strategic roadmap prioritizes Australia as the initial market, emphasizing local delivery and after-sales support while building towards broader synergies across the EV and green energy value chains, where solar generates power, storage optimizes it, software manages it, and NEVs consume it. Cheche is pursuing the expansion through a proposed strategic investment in Long Way Fortune, bringing together its insurance technology expertise with EnergyLIB’s residential storage solutions to advance the broader "Car + Home" green ecosystem.
Hong Kong, Oct 9, 2026 - Everest Medicines (1952.HK) announced the appointments of Lakshmi Srinivasan, PhD, as Senior Vice President, Head of Translational Medicine, and Brandon Coder, PhD, as Vice President, Translational Sciences & Discovery. Both executives are seasoned scientists in mRNA cancer vaccines, with deep experience spanning early discovery through clinical development and leadership roles in oncology vaccine research at Moderna and other leading biopharmaceutical companies. The appointments further strengthen the Company’s global R&D capabilities in mRNA therapeutics, and support the continued advancement of its proprietary mRNA platform and pipeline. At Everest, they will drive clinical development of the Company’s mRNA programs and expand Everest’s presence in the United States, in line with the Company’s global mRNA R&D strategy, while working closely with the China R&D team. The two scientists previously held leadership roles at Moderna, where they contributed to its mRNA cancer vaccine programs, including mRNA-4157/V940. Their experience spanning early-stage research through clinical development will support the advancement of Everest's proprietary mRNA platform and global clinical development programs. In August 2026, Moderna and Merck announced that mRNA-4157/V940 in combination with Keytruda met the primary endpoint of recurrence-free survival (RFS) and the key secondary endpoint of distant metastasis-free survival (DMFS) in the Phase 3 INTerpath-001 study. The results represent the first positive Phase 3 readout for an individualized neoantigen therapy (INT) and for an mRNA-based cancer therapy. “We are very pleased to welcome Dr. Srinivasan and Dr. Coder to Everest Medicines as we continue to strengthen our global mRNA R&D capabilities,” said Mr. Yifang Wu, Chairman of the Board of Everest Medicines. “Their deep experience in cancer vaccine research, translational medicine, and clinical development will be highly valuable as we advance our proprietary mRNA platform and broader pipeline. Their appointments reflect our continued commitment to investing in world-class talent and advancing our global mRNA strategy.” Dr. Srinivasan is a seasoned immunologist with 20 years of experience advancing innovative immuno-oncology therapeutics from discovery through clinical development. Her expertise spans cancer vaccines, mRNA-LNP technologies, T-cell therapies, and translational development from preclinical research through clinical proof of concept. Prior to joining Everest Medicines, Dr. Srinivasan served as Executive Director and Head of Oncology Translational Medicine at Moderna Therapeutics from 2023 to 2025. She previously held leadership roles at Repertoire Immune Medicines, Neon Therapeutics, which was later acquired by BioNTech, and Sanofi Oncology. Dr. Srinivasan has played a key role in the clinical translation of personalized neoantigen vaccines and has authored multiple high-profile publications in the field. She served as corresponding author on Phase 1b studies of NEO-PV-01 published in Cell (2020) and Cancer Cell (2022), and co-authored publications on Moderna’s intismeran autogene (mRNA-4157/V940), including the Phase 1 KEYNOTE-603 study published in Cancer Discovery (2024) and the three-year follow-up of the randomized Phase 2b KEYNOTE-942 study published in JCO Oncology Advances (2026). Dr. Coder brings more than 11 years of industry experience advancing T cell immunotherapies from discovery through investigational new drug (IND) submissions and early clinical proof of concept, with expertise in cancer vaccines, mRNA/LNP platform technology, and in vivo CAR therapies. Prior to joining Everest Medicines, Dr. Coder held scientific roles at Moderna from 2019 to 2025, most recently as Associate Scientific Director of Cancer Vaccine Research. He served as research and global pharmacology lead for intismeran autogene (mRNA-4157/V940), which reported positive results from the Phase 3 INTerpath-001 study in August 2026, becoming the first personalized neoantigen therapy and mRNA cancer therapy to achieve success in a Phase 3 clinical study. Dr. Coder also co-invented and led development of the shared-antigen discovery and vaccine design framework for mRNA-4359 and mRNA-4106. He contributed to nine IND submissions as a co-inventor, research lead, or core contributor, and co-authored the Phase 1 KEYNOTE-603 study of mRNA-4157/V940 published in Cancer Discovery (2024). Prior to joining Moderna, Dr. Coder served as Associate Director of Immuno-Oncology Research at Advaxis Immunotherapies, where he developed personalized and off-the-shelf cancer vaccines. Leveraging its proprietary AI+mRNA platform, Everest Medicines is advancing multiple mRNA oncology therapeutic vaccine and in vivo CAR-T programs for oncology and autoimmune diseases. EVM16, a personalized mRNA therapeutic cancer vaccine, has completed its first-in-human clinical data readout, demonstrating a favorable safety and tolerability profile, robust immunogenicity and promising preliminary efficacy. Selected data were presented at the 2026 American Association for Cancer Research (AACR) Annual Meeting. Following the Phase 1a study, EVM16 plans to initiate an investigator-initiated trial (IIT) Phase 1b study in Q4 2026 and launch new indication expansion cohorts for efficacy exploration. The company plans to submit an IND application to the U.S. Food and Drug Administration (FDA) in the first half of 2027. EVM14, an off-the-shelf tumor-associated antigen (TAA) mRNA cancer vaccine, received IND clearance from the U.S. FDA and IND approval from China’s National Medical Products Administration (NMPA) in 2025. The Phase 1 monotherapy dose-escalation study is expected to be completed in Q1 2027.EVM18, an in vivo CAR-T therapy, has initiated an IIT study in autoimmune diseases, with global IND filing underway. EVM15, an off-the-shelf immunomodulatory (IM) cancer vaccine, achieved clinical proof of concept in preclinical studies in 2025, with a clinical candidate subsequently selected. The Company plans to advance preparations for the Investigational New Drug (IND) application for EVM15 in 2026.
BRUSSELS, BELGIUM, Oct 9, 2026 - Most recently, the Airwheel SE3SX Smart Rideable Cabin Suitcase was honored with a 2026 European Product Design Award (EPDA) Winner title, marking yet another milestone in the brand's relentless pursuit of innovation. Airwheel, a pioneering smart mobility brand, has cemented its position as a global design leader with its intelligent rideable luggage series accumulating over 100 prestigious international awards across the United States, Europe, Japan, Italy, Germany, France, and London. The EPDA, alongside the MUSE Design Awards and IDEA Awards—all established by the International Awards Associate (IAA)—represent the pinnacle of global industrial design recognition. An international jury evaluates entries across innovation, aesthetic expression, practical implementation, human-machine interaction, and user experience. Airwheel's repeated success across these platforms underscores its design philosophy: "Let design return to real travel." Award-Winning Products Under the Spotlight Airwheel SE3S Smart Electric Suitcase Award Portfolio: 2023 MUSE Design Award, IDA Award, Italy IIDA Award; 2024 French Design Award, London Design Award (Best of Year), American Good Design Award (Silver), Paris DNA Design Award, NY Product Design Award (Silver); 2025 German National Design Award (Winner), Italy A' Design Award (Silver) MUSE Jury Commentary: "The Airwheel SE3S revolutionizes the traditional suitcase by integrating electric rideability with smart storage. Its patented high-strength frame and modular detachable lithium battery enable seated mobility while meeting stringent aviation regulations—delivering an effortless, elegant travel experience for frequent flyers." As the flagship pioneer of Airwheel's rideable luggage line, the SE3S features a 20-inch carry-on form factor combining rideable transportation, smart storage, and on-the-go charging. Its high-strength hard shell and patented reinforced frame support rider weight, while dual-handlebar controls ensure intuitive operation. The modular plug-and-play lithium battery requires no tools for removal and complies with civil aviation standards. Airwheel SE3SX Smart Rideable Cabin Suitcase Award Portfolio: 2026 European Product Design Award (Winner), WGA Creative Global Design Award (Silver), iLuxury International Luxury Award, Titan Innovation Award (Platinum) EPDA Jury Commentary: "The Airwheel SE3SX redefines the value boundary of carry-on luggage as a 'smart travel terminal,' seamlessly integrating high-performance electric drive, intelligent interaction, and aviation-grade lightweight design. Its innovative electric telescopic front-wheel structure enhances riding stability, while Apple Find My and a dedicated smart app deliver natural human-machine interaction. The 73.26Wh detachable battery and TSA lock ensure global compliance—a design benchmark for premium international business travel." The SE3SX packs a 230W high-performance brushless motor delivering speeds up to 9.9km/h, a 95kg load capacity, and 6° hill-climbing capability. Its innovative electric telescopic front-wheel structure extends the wheelbase by 180mm at the touch of a button. The body combines lightweight ABS+PC materials with an aviation-grade aluminum alloy frame, weighing approximately 6.6kg (excluding power bank), with dimensions of 530×360×236mm and a 20L capacity. Features include Apple Find My global tracking, a dedicated smart app, 5V USB charging, a detachable 73.26Wh lithium battery, and a TSA customs lock—approved for both air and high-speed rail travel. Airwheel SE3SXD Ai Luxury Suitcase The SE3SXD elevates the travel experience with an integrated smart interaction system and linked smart handle, enabling one-touch switching between suitcase form and riding mode. Its dual-drive automatic telescopic mechanism extends and retracts the structure with a single touch—transforming luggage into an intelligent travel companion. Airwheel SE3MiniT Electric Hand Suitcase Award Portfolio: 2024 European Design Award, London Design Award (Platinum), NY Product Design Award (Gold), American Good Design Award (Bronze), Paris DNA Award (Honorable Mention), French Design Award (Honorable Mention); 2025 Italy A' Design Award (Silver), World Design Award European Design Award Jury Commentary: "The Airwheel SE3MiniT addresses urban short-distance travel with ultimate lightweight design, distilling complex rideable luggage functions into a pure 'travel light' experience. Its compact form and convenient rideability make city commutes and weekend getaways effortless—showcasing nuanced thinking for segmented smart mobility scenarios." Designed for urban commuting and weekend excursions, the SE3MiniT retains Airwheel's signature rideable functionality in a compact, lightweight body—ideal for high-frequency, short-distance metropolitan travelers. Airwheel SE3SL / SE3SL+ Ai Wheel Airport Boarding Suitcase Award Portfolio: SE3SL—2025 Berlin Design Award (Gold), Shanghai Design Award, US IDEA Award, IAI Design Award, New Quality Award, Japan IDPA Design Award (Silver), 2026 Asian Design Award; SE3SL+—2025 US AIIDA Design Award, Boiling Quality Award (Gold) IDEA Jury Commentary: "The Airwheel SE3SL organically combines smart mobility concepts with mainstream business luggage forms. At just 6.6kg, its ultra-lightweight design integrates rideability, app connectivity, USB charging, and location tracking—achieving an outstanding balance between innovation, user experience, and commercial value. A mature offering for high-frequency business travel." Targeting premium business travelers, the SE3SL/SE3SL+ series integrates rideable transportation, smart app connectivity, USB charging, and Apple Find My tracking—blending aesthetics with practicality for both short-haul and international business scenarios. Airwheel SQ3S Smart Kids Suitcase Award Portfolio: 2025 French Design Award (Gold), MUSE Design Award (Silver), American Good Design Award (Bronze), NY Product Design Award (Gold) French Design Award Jury Commentary: "The Airwheel SQ3S enters the family travel scene with a safety-first design language, achieving a balance of 'storable, rideable, and reassuring' in a children's smart suitcase. Its safety speed-limit design fully considers children's riding safety, making family travel both fun and secure—embodying design's gentle care for real family needs." The SQ3S is Airwheel's dedicated smart suitcase for family travel, combining ample storage with child-friendly rideable fun, featuring a safety speed-limit design for secure, enjoyable family experiences. Meet Airwheel at the 140th Canton Fair Following its continued recognition in international design competitions, Airwheel invites distributors, importers, retailers, business partners, and visitors from around the world to meet its team at the 140th China Import and Export Fair (Canton Fair) in Guangzhou, China. Airwheel will participate across all three phases of the exhibition, presenting its intelligent rideable luggage and smart mobility solutions to international buyers and industry professionals. Visitors will have the opportunity to explore Airwheel’s product portfolio, experience selected products firsthand, learn more about its latest developments in smart travel technology, and discuss potential distribution partnerships and business opportunities. From smart rideable cabin suitcases to its latest intelligent luggage concepts, Airwheel looks forward to connecting with global partners and exploring opportunities to bring innovative mobility solutions to more markets. Global buyers and potential distribution partners are warmly invited to visit Airwheel’s booths and meet the team in person. Exhibition: 140th China Import and Export Fair (Canton Fair) Venue: China Import and Export Fair Complex, Guangzhou, China Phase 2: October 23–27, 2026 | Booth 20.2F19–20 Phase 3: October 31–November 4, 2026 | Booth 20.2J37–38,20.2K11-12, 18.1K04 For international buyers seeking to expand their smart luggage portfolio, explore retail opportunities, or discuss regional distribution, the Canton Fair provides an opportunity to connect directly with Airwheel and learn more about its products and international partnership opportunities. Brand-Level Honors and Future Outlook As a pioneer of the smart rideable luggage category, Airwheel has built a clear and robust competitive moat through core technologies. To date, the company has secured over 600 patents globally, covering motion control algorithms, electric drive systems, intelligent perception, and structural design—including multiple international invention patents. Airwheel's trademarks are registered in over 168 countries and regions, providing a solid foundation for compliant operations, scalable promotion, and long-term brand building across diverse markets. Behind these honors lies over a decade of deep cultivation in the smart mobility sector. From its first German iF Design Award to now holding over 100 international certifications across the US, Europe, Japan, Italy, France, and the UK, Airwheel continues to showcase the power of persistent innovation. Looking ahead, the brand will continue integrating cutting-edge intelligent perception and human-machine interaction technologies—embedding technology into every journey and delivering smart mobility innovations to global markets. About Airwheel Airwheel is a leading smart mobility brand specializing in intelligent rideable luggage and personal mobility solutions. Guided by its design philosophy “Let design return to real travel”, Airwheel combines electric drive, smart interaction and aviation-grade materials to redefine travel experiences. Boasting over 600 global patents and more than 100 international awards, Airwheel, as one of the world’s leading smart mobility device manufacturers, strives to unleash the joy of technology and uphold its corporate culture: “Free Intelligent Life”. Media Contact Company: Airwheel Contact: Media Team Website: https://www.airwheel.net
GUANGZHOU, China and LONDON, Oct. 9, 2026 -- Chelsea Football Club today announced a global partnership, with GAC – one of the world's fastest growing global automotive businesses – which sees them become the club's Official Automotive Partner. The partnership brings together...
FDA approval is based on results from the landmark phase III ATOMIC study, published in The New England Journal of Medicine, which showed Tecentriq plus chemotherapy reduced the risk of disease recurrence or death by 50% compared to chemotherapy alone1 First approved adjuvant immunotherapy regimen for stage III dMMR colon cancer, positioning Tecentriq as a new post-surgery standard of care Nearly 25% of all colon cancers are diagnosed at stage III, and almost one in three patients with stage III colon cancer experience a recurrence within five years2,3 Approval marks the twelfth indication for Tecentriq in the US Basel, 9 October 2026 - Roche (SIX: RO, ROP; OTCQX: RHHBY) announced today that the US Food and Drug Administration (FDA) has approved Tecentriq® (atezolizumab) and Tecentriq Hybreza® (atezolizumab and hyaluronidase-tqjs) in combination with a fluoropyrimidine and oxaliplatin for the adjuvant treatment of stage III deficient DNA mismatch repair (dMMR) colon cancer, a type of tumour characterised by high mutation rates. This approval marks the twelfth indication for Tecentriq in the US. “This approval provides a new adjuvant treatment option for people with stage III dMMR colon cancer who face a high risk of disease recurrence,” said Levi Garraway, MD, PhD, Roche’s Chief Medical Officer and Head of Global Product Development. “Tecentriq combined with chemotherapy has the potential to become the new standard of care as the first approved immunotherapy-based regimen for this setting.” “Until now, the adjuvant standard of care for stage III colon cancer has not differed based on mismatch repair status,” said Frank A. Sinicrope, MD, Professor of Oncology at the Mayo Clinic and US Principal Investigator for the Alliance ATOMIC trial. “This milestone represents an important therapeutic advance that leverages immunotherapy to target the specific biology of dMMR stage III colon cancer after surgical resection. By reducing the risk of disease recurrence or death by 50%, atezolizumab plus chemotherapy is a practice-changing regimen that can improve clinical outcomes of this group of patients living with colon cancer, one of the most common cancers and a leading cause of cancer-related death.” The FDA approval is based on the landmark phase III ATOMIC study, recently published in The New England Journal of Medicine. ATOMIC demonstrated that adding Tecentriq to modified (m)FOLFOX6 chemotherapy reduced the risk of disease recurrence or death by 50%, compared to chemotherapy alone for people with stage III dMMR colon cancer, as determined by an immunohistochemistry test, such as the VENTANA® MMR RxDx Panel.1 The 36-month disease-free survival was 86% for Tecentriq combined with mFOLFOX6 compared with 76% in the mFOLFOX6 alone group. The safety profile was consistent with previous studies of Tecentriq and mFOLFOX6.1 Colon cancer remains one of the world's most common and deadliest tumours.4 Over one million people are diagnosed globally each year, and nearly 25% of all colon cancers are diagnosed at stage III.2-4 Despite surgery and chemotherapy, nearly 30% of stage III patients experience disease recurrence within five years.2,3 Approximately 15% of colon cancer patients present with dMMR or microsatellite instability-high (MSI-H) tumours, which indicate a higher mutation rate and thus have the potential to respond to immunotherapy.5 Roche is pursuing further regulatory filings for Tecentriq, including with the European Medicines Agency, to bring this immunotherapy-based adjuvant option to patients with dMMR colon cancer worldwide as soon as possible. About the ATOMIC study ATOMIC (A021502, NCT02912559) is a phase III, randomised, open-label, multicentre study investigating the addition of Tecentriq® (atezolizumab) to modified (m)FOLFOX6 chemotherapy (a combination of folinic acid, fluorouracil, and oxaliplatin) in patients with stage III colon cancer who have a deficiency in DNA mismatch repair (dMMR). The trial enrolled 712 patients. Participants were randomised 1:1 to receive either mFOLFOX6 plus Tecentriq for 12 cycles (six months) followed by Tecentriq monotherapy for 13 cycles (an additional six months), or mFOLFOX6 alone for 12 cycles. The primary endpoint is disease-free survival (DFS). The global study in the US was sponsored by the US National Cancer Institute (NCI), part of the National Institutes of Health, and led by the Alliance for Clinical Trials in Oncology (Alliance) with participation from other NCI-funded National Clinical Trials Network (NCTN) groups. Genentech, a member of the Roche Group, provided support for the study through a Cooperative Research and Development Agreement between NCI and Genentech. The trial was led globally by Frank A. Sinicrope, MD, Professor of Oncology at the Mayo Clinic and US Principal Investigator within the Alliance. German participation in this major international academic collaboration was enabled through close cooperation between the Alliance and the AIO-Studien-gGmbH, in partnership with the AIO (Arbeitsgemeinschaft Internistische Onkologie) of the German Cancer Society (Deutsche Krebsgesellschaft, DKG), under the national leadership of Prof. Dr. Anke Reinacher-Schick (Ruhr-Universität Bochum). AIO-affiliated study sites enrolled patients during the later recruitment phase, ensuring access for eligible patients in Germany. About Tecentriq® (atezolizumab) Tecentriq is a monoclonal antibody designed to bind with a protein called PD-L1, which is expressed on tumour cells and tumour-infiltrating immune cells, blocking its interactions with both PD-1 and B7.1 receptors. By inhibiting PD-L1, Tecentriq may enable the re-activation of T cells. Tecentriq may also affect normal cells. Tecentriq has been approved for some of the most aggressive and difficult-to-treat forms of cancer, and is the first PD-(L)1 cancer immunotherapy available in both subcutaneous and intravenous formulations. About Roche in oncology For over 60 years, Roche has delivered transformative medicines and diagnostics, redefining the treatment of some of the most challenging cancers. Driven by a vision of a future where cancer can be cured, we focus our efforts on cancers with the highest societal impact and where we bring deep expertise, including breast, lung, and blood cancers, while pursuing breakthrough innovation in other areas of unmet need. Our pipeline features a diverse array of modalities, from small molecules and antibodies to next-generation ADCs and allogeneic CAR T-cell therapies. By advancing best-in-class precision medicine, pioneering novel combinations, and leveraging key technologies and partnerships, Roche tackles oncology's toughest challenges with the goal of delivering life-changing outcomes for people with cancer. About Roche Roche (SIX: RO, ROP; OTCQX: RHHBY) is a healthcare company uniquely placed to prevent, stop and cure diseases by uniting leading science and technology across diagnostics, medicines and digital solutions. Roche was founded in Basel, Switzerland in 1896 and today is a leading provider of transformative medicines and diagnostics for millions of people in over 150 countries around the world. It is dedicated to tackling healthcare challenges that place the greatest strain on patients, families, communities and healthcare systems. Across its Diagnostics and Pharmaceutical divisions, Roche focuses on areas including oncology, neurology, cardiovascular and metabolic diseases, ophthalmology, infectious diseases and immunology with the aim of providing real and positive change for patients, the people they love and the professionals who care for them. Genentech in the United States is a fully owned subsidiary in the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, a major innovator in the Japanese therapeutic antibody market. For more information, please visit www.roche.com. All trademarks used or mentioned in this release are protected by law. References [1] Sinicrope F, et al. Atezolizumab plus FOLFOX for Stage III Mismatch Repair–Deficient Colon Cancer. N Engl J Med. 2026;394:1155-1166. [2] Gonzalez B, et al. Analyzing recurrence in colorectal cancer: Is a five years follow-up enough? Annals of Oncology. 2024;35(1);11. [3] Nors J et al. Incidence of Recurrence and Time to Recurrence in Stage I to III Colorectal Cancer: A Nationwide Danish Cohort Study. JAMA Oncology. 2024;10(1):54–62. [4] World Health Organization. Cancer [Internet; cited 2026 October]. Available from: https://www.who.int/news-room/fact-sheets/detail/cancer. [5] Boland CR, et al. Microsatellite Instability in Colorectal Cancer. Gastroenterology. 2010;138:2073–2087. Roche Global Media Relations Phone: +41 61 688 88 88 / e-mail: media.relations@roche.com Tristan Schmitz Phone: +41 79 529 70 35Lorena Corfas Phone: +41 79 568 24 95 Simon Goldsborough Phone: +44 797 32 72 915Karsten Kleine Phone: +41 79 461 86 83 Kirti Pandey Phone: +41 79 398 38 53Yvette Petillon Phone: +41 79 961 92 50 Irène Stephan Phone: +41 79 377 83 75Albert Thottiyil Phone: +41 79 775 66 12 Roche Investor Relations Dr Bruno Eschli Phone: +41 61 68-75284 e-mail: bruno.eschli@roche.comDr Sabine Borngräber Phone: +41 61 68-88027 e-mail: sabine.borngraeber@roche.com Dr Birgit Masjost Phone: +41 61 68-84814 e-mail: birgit.masjost@roche.com Investor Relations North America Loren Kalm Phone: +1 650 225 3217 e-mail: kalm.loren@gene.com Attachment Media&Investor Release FDA approval for Tecentriq Tecentriq Hybreza English
Volkswagen presents the new ID. Tiguan, one of the brand’s most important electric models for the years ahead. The new all-round SUV in the high-volume mid-size class succeeds the ID.4 and ID.5 models. The ID. Tiguan’s hallmark feature is its completely redesigned exterior, which gives it the appearance of a vehicle from the next class up. And this impression continues seamlessly into the strikingly high-quality interior: the materials used have resulted in a huge leap forwards in terms of quality, complemented by the newly developed, intuitive cockpit landscape. For the first time, the new SUV will be available with a co-driver display. The electrically powered ID. Tiguan will be launched as early as the beginning of 2027 – in parallel to the current Tiguan with petrol, diesel and hybrid drives. Read on Consumption data: ID. Tiguan (220 kW) - Combined power consumption 17.2-15.7 kWh/100 km; combined CO2 emissions 0 g/km; CO2 class: A. /// Optional equipment.